Literature DB >> 22277808

Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.

Giovanna Fattovich1, Gianluca Svegliati Baroni, Michela Pasino, Irene Pierantonelli, Loredana Covolo, Donatella Ieluzzi, Nicola Passigato, Angelo Tonon, Maria Grazia Faraci, Maria Guido, Francesco Negro.   

Abstract

BACKGROUND AND AIM: The role of insulin resistance in predicting virological response to therapy of chronic hepatitis C is debated. We assessed the association between basal (defined as homeostasis model assessment of insulin resistance (HOMA-IR)>2) and post-load insulin resistance (as oral glucose insulin sensitivity index<9.8 mg/kg/min) with the rapid and sustained virological responses in chronic hepatitis C.
METHODS: Observational prospective study of 124 treatment-naïve patients with chronic hepatitis C not fulfilling the metabolic syndrome criteria, adherent to a standard treatment with pegylated interferon alpha plus ribavirin.
RESULTS: Insulin resistance was detected in 50% (by HOMA-IR) and 29% (by oral glucose insulin sensitivity index) of patients. Independent predictors of rapid virologic response were hepatitis C virus (HCV) genotype 2 (odds ratio 5.66; 95% confidence interval 1.88-17.01), HCV genotype 3 (odds ratio 5.23; 95% confidence interval 1.84-14.84) and lower basal ferritin levels (odds ratio 0.99; 95% confidence interval 0.993-0.998). Independent predictors of sustained virologic response were HCV genotype 2 (odds ratio 19.54; 95% confidence interval 2.29-166.41) and HCV genotype 3 (odds ratio 3.24; 95% confidence interval 1.10-9.58). Rapid virologic response was by itself predictive of sustained virologic response (odds ratio 40.90; 95% confidence interval 5.37-311.53).
CONCLUSIONS: Insulin resistance, measured by both static and dynamic methods, does not predict rapid or sustained virologic response in chronic hepatitis C patients without the metabolic syndrome.
Copyright © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22277808     DOI: 10.1016/j.dld.2011.12.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

Review 1.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 2.  Metabolic factors and chronic hepatitis C: a complex interplay.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Maria Giovanna Minissale; Teresa Li Vigni; Simona Attardo; Emanuele Orlando; Salvatore Petta
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

3.  HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients.

Authors:  Alessandro Grasso; Federica Malfatti; Gabriella Andraghetti; Simona Marenco; Chiara Mazzucchelli; Sara Labanca; Renzo Cordera; Roberto Testa; Antonino Picciotto
Journal:  Gastroenterol Res Pract       Date:  2015-03-03       Impact factor: 2.260

Review 4.  Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?

Authors:  Alessandro Grasso; Federica Malfatti; Roberto Testa
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.